|Mr. Robert B. Jones||Chief Exec. Officer, Pres and Director||393k||N/A||58|
|Mr. Peter A. Clemens||Chief Financial Officer, Sr. VP and Sec.||286k||N/A||64|
|Dr. Albert W. Brzeczko Ph.D.||VP of Technical Affairs||291k||N/A||60|
|Mr. James F. Emigh R.PH.||VP of Corp. Devel.||N/A||N/A||61|
|Mr. J. Bradley Rivet||VP of Marketing||N/A||N/A||63|
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide. The company was founded in 1935 and is based in Palatine, Illinois.
Acura Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.